Spatial Metabolomics Reveals How Tirzepatide Inhibits Colorectal Cancer via Glucose Metabolic Reprogramming We are excited to share a recent publication in Advanced Science titled The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Attenuates Colon Cancer Development by Regulating Glucose Metabolism. In this study, the authors employed spatial metabolomics services provided by MetwareBio to explore the metabolic mechanisms by which tirzepatide (TZP)a dual GIP and GLP-1 receptor agonist initially approved for type 2 diabetesexerts potent anti-tumor effects in colorectal cancer (CRC)
Stimulates the appetite and is helpful in lactating mothers
However, this does not mean patients never experience this symptomrather, it reflects that dark urine typically results from secondary effects rather than direct drug action
The dosing device is typically a prefilled pen
N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia
Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves ophthalmopathy: results of a prospective, single-blind, randomized study
